Abstract: The invention provides therapeutic methods for inhibiting, ameliorating or alleviating the hyperproliferative cellular activity of diseases of the prostate, e.g., prostatic cancer and prostatic hyperplasia, which includes administering to a patient in need thereof an active vitamin D analogue and another anticancer agent. Cell differentiation is promoted, induced or enhanced without causing to the patient dose-limiting hypercalcemia and hypercalciuria.

Abstract: The invention provides therapeutic methods for inhibiting, ameliorating or alleviating the hyperproliferative cellular activity of diseases of the breast, e.g., breast cancer, which includes administering to a patient in need thereof an active vitamin D analogue and another anticancer agent. Cell differentiation is promoted, induced or enhanced without causing to the patient dose-limiting hypercalcemia and hypercalciuria.

Abstract: The present invention provides a method of increasing or maintaining blood concentrations of 1,25-dihydroxyvitamin D in a patient by administering an amount of 1?-hydroxyvitamin D2. The invention also provides a method of concurrently lowering or maintaining plasma intact parathyroid hormone levels, increasing or maintaining serum calcium levels, maintaining serum phosphorous levels, or increasing or maintaining serum 1,25-dihydroxyvitamin D levels in a human patient by administering to the patient an amount of 1?-hydroxyvitamin D2. The invention also provides a method of reducing the risk of over suppression of plasma intact parathyroid hormone levels in a patient undergoing treatment for elevated levels of plasma intact parathyroid hormone, by administering 1?-hydroxyvitamin D2 in an amount sufficient to decrease elevated intact parathyroid hormone levels while avoiding an abnormally low bone turnover rate.

Abstract: The present invention is directed to a conjugate which includes at least one vitamin D moiety thereof and at least one targeting molecule moiety to pharmaceutical compositions of the conjugate, and to methods for using the conjugate for target-specific delivery of vitamin D or analogs thereof to tissues in need thereof. When a particularly preferred form is administered to a patient, the targeting molecule component of the conjugate of this invention seeks out and binds to a tissue of interest, such as bone or tumor tissue, where the vitamin D has a therapeutic effect.

Abstract: The invention provides a stabilized 1?-hydroxyvitamin D (“SHVD”) which is particularly well suited for pharmaceutical formulations.

Abstract: The invention provides a stabilized 1?-hydroxyvitamin D (“SHVD”) which is particularly well suited for pharmaceutical formulations.

Abstract: This invention relates to multi-use dispensing vessels containing pharmaceutical formulations of active vitamin D compounds.

Abstract: This invention relates to multi-use dispensing vessels containing pharmaceutical formulations of active vitamin D compounds, and also to plastic blow fill containers containing active vitamin D formulations.

Abstract: The invention relates to pharmaceutical formulations of lipophilic therapeutic agents in which such agents are solubilized in largely aqueous vehicles, and processes for preparing and using the same.

Abstract: This invention relates to a method for treating or preventing hyperthyroidism secondary to chronic kidney disease by administering a sufficient amount of an active vitamin D analog utilizing a variety of effective treatment protocols.

Abstract: The invention provides therapeutic methods for inhibiting, ameliorating or alleviating the hyperproliferative cellular activity of diseases of the prostate, e.g., prostatic cancer and prostatic hyperplasia, which includes administering to a patient in need thereof an active vitamin D analogue. Cell differentiation is promoted, induced or enhanced without causing to the patient dose-limiting hypercalcemia and hypercalciuria.

Abstract: Methods for the utilization of hypocalcemic vitamin D analogs to inhibit the hyperproliferation of malignant or neoplastic cells without incidence of hypercalcemia.

Abstract: A method of inhibiting the hyperproliferation of malignant or neoplastic cells, comprising treating the cells with an antiproliferative amount of 1&agr;,24(S)-dihydroxyvitamin D2. The method also includes the co-administration of cyotoxic agents with the 1&agr;,24(S)-dihydroxyvitamin D2.

Abstract: Methods utilizing active vitamin D analogs for the treatment of malignancy-associated hypercalcemia. Methods comprise the application of an effective amount of a hypocalcemic vitamin D compound to alleviate hypercalcemia, lower serum parathyroid hormone related protein (PTHrP) levels.

Abstract: The present invention is directed to a conjugate which includes at least one vitamin D moiety thereof and at least one targeting molecule moiety to pharmaceutical compositions of the conjugate, and to methods for using the conjugate for target-specific delivery of vitamin D or analogs thereof to tissues in need thereof. When a particularly preferred form is administered to a patient, the targeting molecule component of the conjugate of this invention seeks out and binds to a tissue of interest, such as bone or tumor tissue, where the vitamin D has a therapeutic effect.

Abstract: Methods for the utilization of hypocalcemic vitamin D analogs to inhibit the hyperproliferation of malignant or neoplastic cells without incidence of hypercalcemia.

Abstract: Methods utilizing active vitamin D analogs for the inhibition of angiogenesis associated with malignant and neoplasmic cells. Methods comprise the application of an effective amount of a hypocalcemic vitamin D compound to inhibit the angiogenesis of malignant cells, inducing the apoptosis of malignant cells, and regressing the growth of tumorous cells.

Abstract: Methods utilizing active vitamin D analogs for the treatment of malignancy-associated hypercalcemia. Methods comprise the application of an effective amount of a hypocalcemic vitamin D compound to alleviate hypercalcemia, lower serum parathyroid hormone related protein (PTHrP) levels.

Abstract: A method of inhibiting the hyperproliferation of malignant or neoplastic cells, comprising treating the cells with an antiproliferative amount of 1&agr;,24(S)-dihydroxyvitamin D2. The method also includes the co-administration of cyotoxic angents with the 1&agr;,24(S)-dihydroxyvitamin D2.

Abstract: The invention provides therapeutic methods for inhibiting, ameliorating or alleviating the hyperproliferative cellular activity of diseases of the prostate, e.g., prostatic cancer and prostatic hyperplasia, which includes administering to a patient in need thereof an active vitamin D analogue. Cell differentiation is promoted, induced or enhanced without causing to the patient dose-limiting hypercalcemia and hypercalciuria.